Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate

Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate The use of plasma‐derived coagulation factor concentrates has been marked by the transmission of viral agents. Infusions of factor IX complex concentrates have been additionally complicated by inappropriate thrombosis. Use of these concentrates in the neonate, in those with liver disease, and in surgical patients results in increased risk for this complication. Twenty patients have been infused with a purified coagulation factor IX concentrate for fall‐off and recovery studies. A two‐compartment model indicated an initial phase half‐life of 4.06 ± 2.86 hr and a β phase half‐life of 20.0 ± 3.8 hr following the administration of AlphaNine®, Coagulation Factor IX (Human). In vivo recovery was 62.7% ± 13.8%, with an average factor IX coagulant level of 73% ± 16% at 15 min after the infusion of a mean dose of 45 U/kg. Thirteen previously transfused patients with hemophilia B underwent major orthopedic or general or dental surgery using this purified factor IX. Operative outcomes were excellent in all patients. No excessive bleeding was noted. There was no laboratory or clinical evidence for a disseminated intravascular coagulopathy. The excellent surgical outcomes observed in this multitransfused group with biochemical evidence for active liver disease demonstrates the utility and safety of a purified coagulation factor IX concentrate. © 1992 Wiley‐Liss, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Hematology Wiley

Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate

Download PDF
6 pages

Loading next page...
 
/lp/wiley/coagulation-factor-ix-successful-surgical-experience-with-a-purified-H8bYDGFjJi

References (30)

Publisher
Wiley
Copyright
Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company
ISSN
0361-8609
eISSN
1096-8652
DOI
10.1002/ajh.2830400310
Publisher site
See Article on Publisher Site

Abstract

The use of plasma‐derived coagulation factor concentrates has been marked by the transmission of viral agents. Infusions of factor IX complex concentrates have been additionally complicated by inappropriate thrombosis. Use of these concentrates in the neonate, in those with liver disease, and in surgical patients results in increased risk for this complication. Twenty patients have been infused with a purified coagulation factor IX concentrate for fall‐off and recovery studies. A two‐compartment model indicated an initial phase half‐life of 4.06 ± 2.86 hr and a β phase half‐life of 20.0 ± 3.8 hr following the administration of AlphaNine®, Coagulation Factor IX (Human). In vivo recovery was 62.7% ± 13.8%, with an average factor IX coagulant level of 73% ± 16% at 15 min after the infusion of a mean dose of 45 U/kg. Thirteen previously transfused patients with hemophilia B underwent major orthopedic or general or dental surgery using this purified factor IX. Operative outcomes were excellent in all patients. No excessive bleeding was noted. There was no laboratory or clinical evidence for a disseminated intravascular coagulopathy. The excellent surgical outcomes observed in this multitransfused group with biochemical evidence for active liver disease demonstrates the utility and safety of a purified coagulation factor IX concentrate. © 1992 Wiley‐Liss, Inc.

Journal

American Journal of Hematology – Wiley

Published: Jul 1, 1992

There are no references for this article.